CA-ARIMA-GENOMICS
16.3.2020 13:02:13 CET | Business Wire | Press release
Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of genome structure information toward medical research, diagnosis and therapy, announced today the full commercial launch of the HiChIP application built on its existing Arima-HiC platform. With this launch, researchers can now obtain long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest from a single experiment, enabling speed to discovery and publication with reduced costs.
This public launch brings to a close successful market development and beta testing programs that yielded further proof of market need, improved product performance with enhanced quality control, and delivered valuable feedback from customer validations. “We are very pleased with the data obtained with the Arima HiChIP protocol,” said Tamas Ordog, Professor of Physiology at Mayo Clinic. “The results show great reproducibility and excellent overall quality, and the kit saves time and sequencing cost. We particularly value the straightforward quality control steps and the ease of use – overall, Arima HiChIP is of great value.” Key opinion leader Peter Scacheri, Professor at Case Western University and Member of the Case Comprehensive Cancer Center, stated, “We are pleased with the informative nature and quality of the Arima-HiChIP data.”
HiChIP data can inform mechanistic underpinnings of gene regulation and how it eventually leads to a disease state. "Enriching for active chromatin features through H3K27ac or H3K4me4 HiChIP enables our discovery of high-resolution chromatin looping events that facilitate gene control in muscle stem cells during the transition from a state of quiescence to their commitment toward differentiation into regenerating myofibers, during muscle regeneration in healthy conditions, aging or diseases such as muscular dystrophies,” said Lorenzo Puri, Professor, Development, Aging and Regeneration Program at Sanford Burnham Prebys Medical Discovery Institute.
Recognizing the value of HiChIP and in the absence of commercially validated kits, the scientific community had been homebrewing this biochemistry. “We have been homebrewing HiChIP because it provides critical insights that were previously obtained by performing separate HiC and ChIP-Seq experiments,” said Yin Shen, Assistant Professor at University of California, San Francisco, who studies the genetics of Neuropsychiatry. “Arima-HiChIP generated superior data quality and reproducibility even with our most challenging terminally differentiated neuronal samples, where our homebrew version previously failed, thus saving us from substantial repeat costs.”
Feedback and data generated by early customers also helped to understand the positioning of HiChIP in the context of related assays such as HiC and ChIP-Seq. In particular, while HiC reflects the global framework of genome organization, HiChIP enriches for targeted chromatin interactions originating from specific genomic locations of research interest. Depending on the requirements of the study, a researcher can leverage comprehensive HiC, finer resolution HiChIP, or, both. “The combined analysis of this HiChIP data with our genome-wide HiC data is pivotal to our understanding of both the broader compartmentalization and topological frameworks that influence gene regulation, but also the finer resolution connections between specific cis-regulatory elements," added Puri.
Importantly, because the chromatin interaction data from HiChIP reflect the inherent folding (and misfolding) of the genome in three-dimensions, this can also inform aspects of misregulated genes on a rearranged cancer chromosome – critical insights missed from traditional ChIP-Seq experiments. “Not only do we observe intra-chromosomal cis-regulatory interactions across cancer genomes, but also inter-chromosomal ectopic cis-regulatory interactions on rearranged chromosomes. We think this data will help better delineate the relationship between genetic and epigenetic driver events in cancer,” added Scacheri.
In response to customer needs for data analysis, the company collaborated with academic partners to optimize community-validated open-source bioinformatics tools such as MAPS. The Arima MAPS pipeline automatically outputs easily understandable quality control statistics and upon user’s push-button to proceed, it generates chromatin interaction heatmaps and arc plots to be readily visualized in genome browsers. In addition to the streamlined data analyses, the company’s focus to enhance customer service and support experience is part of its sustained efforts to expedite sample-to-discovery and publication. “The Arima Technical Support Team has been outstanding,” added Ordog.
The company has developed HiChIP on its existing Arima-HiC platform to enable both HiC and HiChIP from one universal Arima kit. Additionally, the company has scaled its operations and strengthened its commercial team to make these kits globally accessible. “The launch of our customer-validated Arima-HiChIP kits and services marks a significant milestone, because it enables commercialization of both a targeted HiC approach and also an enhancement to traditional ChIP-Seq,” said Joseph Spidle, Commercial Director at Arima Genomics. “Our goal is to add meaningful and scientifically relevant applications to the Arima-HiC platform as we democratize the availability of genomic structural insights to accelerate basic and disease related research.”
About Arima Genomics
Arima Genomics, Inc. is a biotechnology company that aims to accelerate the understanding of genome sequence and structure and their role in health, disease, and species evolution. For additional information, please visit: http://www.arimagenomics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005137/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release
Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
